These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 30540568)

  • 1. Cabergoline in the Management of Residual Nonfunctioning Pituitary Adenoma: A Single-Center, Open-Label, 2-Year Randomized Clinical Trial.
    Batista RL; Musolino NRC; Cescato VAS; da Silva GO; Medeiros RSS; Herkenhoff CGB; Trarbach EB; Cunha-Neto MB
    Am J Clin Oncol; 2019 Feb; 42(2):221-227. PubMed ID: 30540568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine receptor subtype 2 expression profile in nonfunctioning pituitary adenomas and in vivo response to cabergoline therapy.
    Vieira Neto L; Wildemberg LE; Moraes AB; Colli LM; Kasuki L; Marques NV; Gasparetto EL; de Castro M; Takiya CM; Gadelha MR
    Clin Endocrinol (Oxf); 2015 May; 82(5):739-46. PubMed ID: 25418156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cabergoline should be attempted in progressing non-functioning pituitary macroadenoma.
    Greenman Y; Bronstein MD
    Eur J Endocrinol; 2021 Aug; 185(4):D11-D20. PubMed ID: 34288884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists.
    Greenman Y; Cooper O; Yaish I; Robenshtok E; Sagiv N; Jonas-Kimchi T; Yuan X; Gertych A; Shimon I; Ram Z; Melmed S; Stern N
    Eur J Endocrinol; 2016 Jul; 175(1):63-72. PubMed ID: 27150495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of cabergoline therapy in patients with non-functioning pituitary adenomas: A single center clinical experience.
    Vargas-Ortega G; González-Virla B; Balcázar-Hernández L; Arreola-Rosales R; Benitez-Rodríguez FJ; López Félix B; Mercado M
    Arch Endocrinol Metab; 2022 Sept 08; 66(4):506-511. PubMed ID: 35758837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cabergoline treatment for surgery-naïve non-functioning pituitary macroadenomas.
    Ayalon-Dangur I; Turjeman A; Hirsch D; Robenshtok E; Tsvetov G; Gorshtein A; Masri H; Shraga-Slutzky I; Manisterski Y; Akirov A; Shimon I
    Pituitary; 2024 Feb; 27(1):52-60. PubMed ID: 38064148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study.
    Florio T; Barbieri F; Spaziante R; Zona G; Hofland LJ; van Koetsveld PM; Feelders RA; Stalla GK; Theodoropoulou M; Culler MD; Dong J; Taylor JE; Moreau JP; Saveanu A; Gunz G; Dufour H; Jaquet P
    Endocr Relat Cancer; 2008 Jun; 15(2):583-96. PubMed ID: 18509006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minor tumour shrinkage in nonfunctioning pituitary adenomas by long-term treatment with the dopamine agonist cabergoline.
    Lohmann T; Trantakis C; Biesold M; Prothmann S; Guenzel S; Schober R; Paschke R
    Pituitary; 2001 Aug; 4(3):173-8. PubMed ID: 12138990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Dopamine Agonists in Pituitary Adenomas.
    Giraldi EA; Ioachimescu AG
    Endocrinol Metab Clin North Am; 2020 Sep; 49(3):453-474. PubMed ID: 32741482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of cabergoline on tumor remnant after surgery in nonfunctioning pituitary adenoma.
    Iglesias P; Biagetti B; Araujo-Castro M; Alcázar V; Guerrero-Pérez F; Rivero N; Casteràs A; Gómez CG; Izquierdo BG; Torres VV; Pascual-Corrales E; Pavón I; Villabona C; Cordido F; Díez JJ
    J Neurooncol; 2022 Nov; 160(2):351-359. PubMed ID: 36355257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine agonist therapy of clinically non-functioning pituitary macroadenomas. Is there a role for 123I-epidepride dopamine D2 receptor imaging?
    de Herder WW; Reijs AE; Feelders RA; van Aken MO; Krenning EP; Tanghe HL; van der Lely AJ; Kwekkeboom DJ
    Eur J Endocrinol; 2006 Nov; 155(5):717-23. PubMed ID: 17062888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
    Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
    Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ACTH silent adenoma shrinking under cabergoline.
    Petrossians P; Ronci N; Valdés Socin H; Kalife A; Stevenaert A; Bloch B; Tabarin A; Beckers A
    Eur J Endocrinol; 2001 Jan; 144(1):51-7. PubMed ID: 11174837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery.
    Meij BP; Lopes MB; Ellegala DB; Alden TD; Laws ER
    J Neurosurg; 2002 Feb; 96(2):195-208. PubMed ID: 11838791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Shrinkage of a PRL-secreting pituitary macroadenoma resistant to cabergoline.
    Cannavò S; Bartolone L; Blandino A; Spinella S; Galatioto S; Trimarchi F
    J Endocrinol Invest; 1999 Apr; 22(4):306-9. PubMed ID: 10342366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas.
    Ferone D; Lastoria S; Colao A; Varrella P; Cerbone G; Acampa W; Merola B; Salvatore M; Lombardi G
    J Clin Endocrinol Metab; 1998 Jan; 83(1):248-52. PubMed ID: 9435450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonfunctioning pituitary adenomas: association of Ki-67 and HMGA-1 labeling indices with residual tumor growth.
    Šteňo A; Bocko J; Rychlý B; Chorváth M; Celec P; Fabian M; Belan V; Šteňo J
    Acta Neurochir (Wien); 2014 Mar; 156(3):451-61; discussion 461. PubMed ID: 24452592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of non-functioning pituitary adenoma with cabergoline: a systematic review and meta-analysis.
    Botelho MS; Franzini ÍA; Nunes-Nogueira VDS; Boguszewski CL
    Pituitary; 2022 Dec; 25(6):810-818. PubMed ID: 35902444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postoperative treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists decreases tumour remnant growth.
    Greenman Y; Tordjman K; Osher E; Veshchev I; Shenkerman G; Reider-Groswasser II; Segev Y; Ouaknine G; Stern N
    Clin Endocrinol (Oxf); 2005 Jul; 63(1):39-44. PubMed ID: 15963059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of cabergoline in a pituitary adenoma secreting follicle-stimulating hormone.
    Leese G; Jeffreys R; Vora J
    Postgrad Med J; 1997 Aug; 73(862):507-8. PubMed ID: 9307745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.